Financial Performance - The company's operating revenue for the third quarter was ¥684,026,058.95, a decrease of 4.55% compared to the same period last year[5]. - The net profit attributable to shareholders was ¥139,440,739.05, an increase of 10.89% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥108,414,674.24, down 12.90% from the previous year[5]. - The basic earnings per share for the quarter was ¥0.2800, a decrease of 6.67% compared to the same period last year[5]. - The total profit amounted to CNY 504,028,174.17, compared to CNY 394,684,389.63 in the previous period, reflecting an increase of about 27.7%[36]. - The operating profit reached CNY 505,255,213.36, up from CNY 392,621,590.85, indicating a growth of approximately 28.7%[36]. - The net profit attributable to shareholders of the parent company was CNY 418,279,088.07, an increase from CNY 323,458,914.31 in the previous period, representing a growth of approximately 29.3%[37]. - The total comprehensive income amounted to CNY 428,899,020.70, compared to CNY 349,903,789.47 in the previous period, reflecting an increase of approximately 22.5%[37]. Assets and Liabilities - The total assets at the end of the reporting period were ¥7,979,553,465.16, reflecting a 4.69% increase from the end of the previous year[5]. - The equity attributable to shareholders increased to ¥7,171,716,020.94, up 5.02% from the previous year[5]. - The company's total liabilities as of September 30, 2022, were CNY 711,315,701.71, compared to CNY 701,299,849.03 at the beginning of the year[30]. - The company's total current assets reached CNY 5,991,275,687.02, up from CNY 5,645,912,964.89 at the beginning of the year[25]. Cash Flow - The cash flow from operating activities showed a significant decline of 67.87% year-on-year, totaling ¥377,007,297.33[5]. - The cash flow from operating activities was CNY 377,007,297.33, down from CNY 1,173,508,351.28 in the previous period, showing a decline of approximately 67.9%[42]. - Cash inflow from investment activities totaled CNY 3,448,467,134.16, significantly higher than CNY 578,069,667.36 in the previous period, marking an increase of about 497.5%[42]. - The net cash flow from investment activities was negative at CNY -778,543,985.54, slightly improved from CNY -788,695,949.14 in the previous period[45]. Investments and Expenses - The company's cash and cash equivalents decreased by 30.60% to ¥1,099,155,602.26 due to investments in financial products[10]. - The company's intangible assets increased by 57.35% to ¥266,665,134.59, primarily due to the transfer of R&D projects[10]. - R&D expenses decreased by 31.85% to ¥35,626,723.74, primarily due to the capitalization of certain projects[13]. - Investment income increased by 587.91% to ¥48,175,581.16, mainly driven by higher returns from financial products[13]. - Cash paid for investments surged by 216.32% to ¥4,150,000,000.00, primarily due to increased purchases of financial products[13]. - The company reported a significant increase in financial expenses by 606.60% to -¥18,322,375.98, due to increased interest income from bank deposits[13]. Strategic Developments - The company established a new subsidiary, Yangcheng Plasma Station, holding an 80% stake, to enhance strategic cooperation in the blood products sector[19]. - The company obtained the drug registration certificate for human coagulation factor VIII in August 2022, enhancing its product line and increasing the value of plasma utilization per ton[20]. - The company's subsidiary, Tianan Pharmaceutical, received the drug registration certificate for acarbose tablets in September 2022, which will strengthen its diabetes medication product line and market competitiveness[21]. - The company is focused on expanding its product offerings and enhancing its market position through strategic product registrations and certifications[20][21]. Other Information - Deferred tax assets rose by 37.23% to ¥37,655,335.12, mainly due to changes in the fair value of financial products[13]. - Long-term borrowings decreased by 100% as they were reclassified to current liabilities[13]. - Other non-current assets increased by 41.14% to ¥52,503,771.62, primarily due to land deposit payments[13]. - Contract liabilities increased by 39.25% to ¥18,067,719.38, reflecting an increase in advance payments received[13]. - The third quarter report has not been audited[46]. - The board of directors of China Resources BoYa Bio-Pharmaceutical Group Co., Ltd. held a meeting on October 24, 2022[47].

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2022, representing a year-on-year growth of 15%[1] - The company's operating revenue for the first half of 2022 was approximately RMB 1.40 billion, representing an increase of 8.02% compared to the same period last year[30] - The net profit attributable to shareholders of the listed company reached approximately RMB 278.84 million, a significant increase of 41.03% year-on-year[30] - The net profit after deducting non-recurring gains and losses was approximately RMB 247.57 million, up 27.28% from the previous year[30] - The basic earnings per share increased to RMB 0.55, reflecting a growth of 19.57% compared to RMB 0.46 in the same period last year[30] - The company achieved total revenue of ¥1,398,718,256.57, an increase of 8.02% year-on-year[70] - The net profit attributable to shareholders was ¥278,838,349.02, reflecting a growth of 41.03% compared to the previous year[70] - Blood products revenue reached ¥692,886,681.76, up 17.01% year-on-year, driven by new product sales starting in April 2021[70] - The diabetes drug segment, operated by Tianan Pharmaceutical, saw a revenue decline of 11.74% to ¥101,198,506.54, primarily due to national procurement policies[70] - The biochemical drug segment, managed by Xinbai Pharmaceutical, experienced a revenue drop of 16.87% to ¥208,451,399.28, attributed to intensified market competition and regional procurement policies[73] Product Development and Market Expansion - New product development includes the launch of two innovative blood products, expected to receive regulatory approval by Q4 2022, which could potentially increase market share by 5%[4] - The company plans to expand its market presence by establishing three new plasma collection stations in key regions, aiming to increase raw material supply by 30%[5] - A strategic acquisition of a competitor is in progress, which is projected to enhance the company's production capacity by 25%[6] - The company aims to become a world-class blood product enterprise, focusing on blood products while stabilizing non-blood product businesses[40] - The company is focusing on expanding its blood products pipeline, with ongoing projects including human coagulation factor VIII and high-concentration immunoglobulin[64] - The company plans to enhance its marketing capabilities and optimize product structure to mitigate the impact of procurement policies on its non-blood products[67] Research and Development - The company has allocated 100 million RMB for R&D in new technologies aimed at improving product quality and production efficiency[7] - The company maintains a dual approach to research and development, combining independent and collaborative efforts with universities and research institutions[55] - The company has established a peptide drug engineering technology research center to strengthen its competitive advantage in biochemical drugs[67] - R&D investment decreased by 43.39% to ¥34,638,320.79 due to lower investment in ongoing product stages[93] - The company aims to enhance R&D investment and collaboration with universities and research institutions to secure product registration certificates for new products[134] Financial Management and Investment - The company does not plan to distribute cash dividends or issue bonus shares for the current fiscal year, focusing instead on reinvestment for growth[9] - The company reported a net decrease in cash and cash equivalents of ¥574,700,096.12, a 1,514.68% decline, attributed to the same recovery of prepayments[93] - The total investment amount during the reporting period was CNY 4,174,967,923.96, representing a 210.51% increase compared to CNY 1,344,552,620.86 in the same period last year[109] - The company plans to allocate all unused raised funds amounting to CNY 99,607.51 million to the "Intelligent Factory for Blood Products (Phase I) Construction Project"[115] - The company has a total of RMB 415,000 million in entrusted financial management, with RMB 345,000 million remaining due and no overdue amounts reported[122] Operational Challenges and Risks - Risks associated with raw material supply shortages were emphasized, particularly the reliance on healthy human plasma, which is currently under tight supply conditions[10] - The company faces risks related to the supply of raw materials, specifically human plasma, which is critical for blood product production, and the supply is currently tight due to regulatory constraints[129] - The company will optimize production capacity and enhance product lines to cope with potential price declines due to national medical policies[136] - The company faces goodwill impairment risks due to the merger with Tianan Pharmaceutical, Xinbai Pharmaceutical, and Fuda Pharmaceutical, which may adversely affect its financial performance[136] Environmental Compliance and Social Responsibility - The company has implemented a comprehensive environmental monitoring system to ensure real-time tracking of volatile organic compounds and energy consumption of environmental facilities[162] - The companies have reported no administrative penalties due to environmental issues during the reporting period[173] - The company has donated nearly 2 million RMB to various social welfare projects, including health initiatives and educational support[185] - The company emphasizes social responsibility, focusing on creating social value while enhancing corporate value[179] - The company has established a "sunshine procurement" policy to enhance supplier management and maintain long-term cooperative relationships[184] Employee Engagement and Training - The company has implemented a "3+1 talent training plan" and achieved a 100% employee training coverage rate with an average training investment of over 700 RMB per employee[181]

Financial Performance - The company's revenue for Q1 2022 was ¥654,635,799.08, a decrease of 4.89% compared to the adjusted revenue of ¥672,101,665.87 in the same period last year[5] - Net profit attributable to shareholders for Q1 2022 was ¥103,554,147.18, representing a 2.80% increase from the adjusted net profit of ¥100,736,164.66 in the previous year[5] - Basic and diluted earnings per share for Q1 2022 were both ¥0.21, down 12.50% from ¥0.24 in the previous year[5] - Total operating revenue for the current period reached ¥654,635,799.08, an increase of 4.1% compared to ¥624,118,627.05 in the previous period[35] - Net profit for the current period was ¥106,852,356.15, compared to ¥103,957,040.08 in the previous period, marking an increase of 2.8%[38] Cash Flow and Liquidity - The net cash flow from operating activities decreased significantly by 86.10%, amounting to ¥22,146,972.56 compared to ¥159,306,575.70 in the same period last year[5] - The company reported a net cash flow from investing activities of -712,158,654.56, compared to -23,839,711.56 in the previous period, indicating a significant increase in investment outflows[46] - The net increase in cash and cash equivalents was -690,691,299.91, compared to -78,882,618.94 in the previous period, showing a substantial decline in cash reserves[46] - The ending balance of cash and cash equivalents was 888,570,197.44, down from 1,579,261,497.35 at the beginning of the period[46] - Cash paid for dividends and interest decreased by 98.37% due to reduced interest expenses[14] Assets and Liabilities - The total assets at the end of Q1 2022 were ¥7,679,391,433.49, reflecting a 0.76% increase from ¥7,621,775,902.48 at the end of the previous year[5] - The total liabilities of the company were RMB 652,063,023.89, down from RMB 701,299,849.03, showing a reduction in liabilities[31] - The company's non-current assets totaled RMB 1,959,146,016.98, a decrease from RMB 1,975,862,937.59[31] - Accounts receivable decreased by 100% due to the cancellation of commercial acceptance settlements in 2022 and the maturity of commercial acceptances in 2021[14] Investments and Expenditures - The company plans to invest RMB 996,075,100.00 in the construction of a blood product intelligent factory, reallocating unused funds from a previous project[24] - Cash paid for purchasing goods and receiving services increased by 57.02% primarily due to increased procurement[14] - Cash paid for investment increased by 726.54% mainly due to the purchase of financial products[14] - The company made significant investments totaling 700,000,000.00, indicating a focus on growth and expansion[46] Changes in Equity and Financial Management - The equity attributable to shareholders increased by 1.52% to ¥6,932,628,390.75 from ¥6,829,074,243.57 at the end of the previous year[5] - The weighted average return on equity decreased by 0.92 percentage points to 1.50% from 2.42% in the previous year[5] - The company recorded a financial expense of -¥6,202,545.54, compared to -¥784,174.50 in the previous period, indicating improved financial management[35] Operational Adjustments and Strategic Focus - The company has made adjustments to its accounting policies, affecting revenue recognition for certain cooperative production agreements[8] - The company is focusing on expanding its market presence through the development of new products and technologies[24] - The company is focusing on strategic investments and may be exploring new technologies and market expansions based on the significant cash outflows for investments[46] Other Financial Metrics - Research and development expenses were ¥6,870,470.10, down from ¥8,165,544.65, reflecting a decrease of 15.8%[35] - Other income for the current period was ¥1,702,903.79, up from ¥1,081,046.33, representing an increase of 57.5%[38] - The report for the first quarter was not audited, which may affect the reliability of the financial data presented[47]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2021, representing a year-on-year increase of 15%[6]. - The net profit attributable to shareholders was RMB 300 million, an increase of 20% compared to the previous year[6]. - The total operating revenue for 2021 was ¥2,650,528,421.87, representing a 5.47% increase compared to 2020[28]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was ¥293,492,852.21, an 18.00% increase from the previous year[28]. - The net cash flow from operating activities reached ¥1,345,377,085.21, showing an 87.23% increase year-on-year[28]. - The company reported quarterly revenues of ¥624,118,627.05, ¥670,715,460.47, ¥716,663,666.72, and ¥639,030,667.63 for Q1 to Q4 respectively[35]. - The net profit attributable to shareholders for Q3 was ¥125,743,618.59, while Q4 saw a decline to ¥21,070,085.21[35]. - The company achieved total revenue of ¥2,650,528,421.87, a year-on-year increase of 5.47%[78]. - Operating profit reached ¥443,056,519.61, reflecting a growth of 33.67% compared to the previous year[78]. - Net profit attributable to shareholders was ¥344,528,999.52, marking a 32.48% increase year-on-year[78]. Market Expansion and Product Development - The company plans to distribute a cash dividend of RMB 1.5 per 10 shares, totaling approximately RMB 75 million[6]. - User data indicates a 25% increase in the number of plasma donors, reaching 500,000 donors by the end of 2021[6]. - The company is expanding its market presence with the establishment of three new plasma collection stations in 2022[6]. - The company aims to launch two new products in the next fiscal year, targeting a market share increase of 10%[6]. - The company plans to launch new products, including the VIII factor in 2022, enhancing its product line[53]. - The company aims to integrate resources in the blood products industry under the control of its major shareholder, China Resources Pharmaceutical[47]. - The company is committed to ensuring a stable supply of raw plasma while improving production quality and process control[60]. - The company aims to become a leading player in the blood products industry, targeting over 30 plasma collection stations and an annual plasma collection of over 1,800 tons during the 14th Five-Year Plan period[171]. Research and Development - Research and development expenses increased by 30% to RMB 150 million, focusing on new product innovations[6]. - The company has a strong R&D capability, continuously increasing investment in research and development, focusing on immunoglobulin and factor products[94]. - The number of R&D personnel increased by 5.39% to 215, with 13.01% of the workforce dedicated to R&D[127]. - The company emphasizes innovation in its R&D model, combining independent and collaborative research efforts[71]. - The company plans to enhance its plasma station management capabilities and improve operational efficiency through cost control and the establishment of benchmark stations[172]. - The company intends to strengthen its innovation and R&D capabilities, with a focus on increasing R&D investment and improving project management for new product approvals[172]. Financial Management and Investments - The company raised a total of RMB 2,456,539,997.75 through a private placement of 78,308,575 shares at RMB 31.37 per share, with a net amount of RMB 2,399,757,417.40 after deducting issuance costs[149]. - The company reported a significant increase in cash and cash equivalents, reaching ¥1,583,695,335.14, which represents 20.78% of total assets, up from 14.59% at the beginning of the year, an increase of 6.19%[137]. - The company experienced a substantial increase in investment activities, with total investments amounting to ¥4,080,078,185.47, a 520.87% increase compared to the previous year[145]. - The company has committed to using raised funds strictly according to the management system, ensuring funds are used for investment projects[149]. - The company has established a strict production management system to ensure compliance with GMP standards in its manufacturing processes[74]. Competitive Position and Industry Outlook - The blood products market in China is expected to grow from over ¥400 billion in 2021 to around ¥1 trillion by the end of the 14th Five-Year Plan[52]. - The company is a leading producer of blood products in China, offering 22 specifications across 8 product types, including human albumin and immunoglobulin[59]. - The company has established a strong competitive advantage in the biochemical drug sector, with 40 product types and 63 specifications across various medical fields[55]. - The company has a strong technical foundation and has continuously developed new products, maintaining a competitive edge in the industry[53]. - The company is focused on building a comprehensive cost capability for its specialty products while collaborating with leading CROs to develop competitive formulation products[181]. Governance and Compliance - The company held a shareholders' meeting in accordance with relevant laws and regulations, ensuring equal rights for all shareholders, especially minority shareholders[200]. - The latest updates to the company's governance documents include the President's Work Guidelines and the Articles of Association, disclosed on January 28, 2022, and January 13, 2022, respectively[198]. - The company has revised its internal regulations to enhance compliance and risk management, ensuring the protection of shareholder rights[198]. - The company is committed to strict compliance with safety and quality management regulations, aiming to prevent EHS and quality incidents[173].

Financial Performance - The company's operating revenue for Q3 2021 was ¥716,663,666.72, representing a 12.74% increase compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2021 was ¥125,743,618.59, a significant increase of 100.36% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥124,478,318.81, reflecting a 95.32% increase compared to the previous year[3]. - The basic earnings per share for Q3 2021 was ¥0.30, doubling from ¥0.15 in the same period last year[6]. - The net cash flow from operating activities for the period was ¥1,173,508,351.28, an increase of 143.65% year-on-year[6]. - Total operating revenue for the period reached ¥2,011,497,754.24, an increase from ¥1,857,199,835.38 in the previous period, representing a growth of approximately 8.1%[37]. - The net profit for the current period is CNY 332,803,307.30, an increase from CNY 235,535,446.41 in the previous period, representing a growth of approximately 41.3%[40]. - The total comprehensive income for the current period is CNY 349,903,789.47, compared to CNY 235,535,446.41 in the previous period[40]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,423,625,188.78, up 5.14% from the end of the previous year[6]. - The company's equity attributable to shareholders was ¥4,435,636,850.72, showing a growth of 7.98% compared to the previous year[5]. - Total liabilities decreased to ¥901,590,407.17 from ¥966,078,096.11, showing a reduction of approximately 6.7%[36]. - The company's equity attributable to shareholders was CNY 4,107,903,650.55, indicating a strong equity position[58]. Cash Flow and Investments - Cash and cash equivalents increased by 43.67% to ¥1,083,129,984.54, primarily due to the receipt of equity transfer payments from Luoyisheng Biotechnology and the recovery of advance payments from Danxia Biotechnology[13]. - The company reported a net cash outflow from investing activities of CNY -788,695,949.14, worsening from CNY -279,228,918.97 in the previous period[48]. - The company’s cash paid for investment activities increased by 198.68% to ¥1,311,960,000.00, primarily due to increased purchases of financial products[16]. Shareholder Information - The company’s total number of ordinary shareholders at the end of the reporting period was 25,182, with the largest shareholder, China Resources Pharmaceutical Group, holding 16.00% of shares[17]. - The largest shareholder, China Resources Pharmaceutical Holdings Co., Ltd., holds 69,331,978 shares, representing 29.17% of the total share capital after the transfer of shares from Gaotejia Group[23]. - The company’s total share capital after the recent transactions stands at 126,381,618 shares[23]. Strategic Initiatives - The company is actively expanding its market presence through strategic acquisitions and partnerships, enhancing its competitive position in the biopharmaceutical sector[20]. - The company has signed a framework agreement to transfer 75% equity in Guangdong Fuda Pharmaceutical Co., Ltd. to its major shareholder, China Resources Pharmaceutical, with the price to be determined based on an evaluation report[25]. - The company plans to transfer 11.68% equity in Luoyi (Wuxi) Biopharmaceutical Co., Ltd. for a total price of RMB 192.72 million, with 10% being sold to Chengdu Pruibang for RMB 165 million[24]. Financial Reporting and Compliance - The company corrected accounting errors affecting previously reported revenues and costs, but this did not impact total assets or net profits[8]. - The company has implemented new leasing standards effective from January 1, 2021, impacting financial reporting[59]. - The third quarter report for 2021 was not audited, which may affect the reliability of the financial data presented[59]. Operational Efficiency - The company reported a significant increase in cash flow, reflecting improved operational efficiency and financial health[29]. - The company is focusing on enhancing management efficiency through the delegation of operational management to its major shareholder's subsidiary[25]. - Financial expenses decreased by 128.84% to -¥2,593,045.47, attributed to reduced loans and interest expenses[16].

Financial Performance - The company reported a significant increase in revenue for the first half of 2021, with total revenue reaching RMB 500 million, representing a 20% year-over-year growth[25]. - The company's operating revenue for the reporting period was ¥1,294,834,087.52, a decrease of 6.00% compared to the previous year's adjusted revenue of ¥1,221,522,418.99[35]. - Net profit attributable to shareholders was ¥197,715,295.72, representing an increase of 22.72% from the previous year's net profit of ¥161,112,708.06[35]. - The net cash flow from operating activities reached ¥996,439,906.80, showing a significant increase of 312.97% compared to the previous year's cash flow of ¥241,287,085.73[35]. - Basic earnings per share rose to ¥0.46, up 21.05% from ¥0.38 in the same period last year[35]. - The company achieved total operating revenue of ¥1,294,834,087.52, a year-on-year increase of 6.00%[72]. - The operating profit reached ¥243,429,511.13, reflecting a growth of 21.71% compared to the previous year[72]. - The blood products business generated total revenue of ¥592,149,251.96, a year-on-year growth of 26.39%, accounting for 45.73% of total revenue[72]. - The net profit from the blood products business was ¥161,400,559.30, up 50.51% year-on-year, representing 81.63% of the net profit attributable to shareholders[72]. Research and Development - The company plans to invest RMB 100 million in research and development for innovative blood products in the next fiscal year[25]. - The company is focused on enhancing its R&D capabilities through partnerships with universities and research institutions, aiming for innovation in product development[62]. - The company is committed to enhancing R&D investment to accelerate the development of coagulation factor products and increase its product variety[153]. - Research and development investment increased by 45.62% to ¥61,184,670.92 from ¥42,015,753.49, indicating a significant focus on innovation[102]. - The company is advancing its R&D pipeline, with key products including human coagulation factor VIII and high-concentration (10%) intravenous immunoglobulin, with clinical trial applications approved[78]. Market Expansion and Strategy - The company has set a target to expand its production capacity by 30% over the next two years to meet increasing market demand[25]. - Market expansion efforts include entering two new provinces, which are projected to increase revenue by an additional RMB 50 million annually[25]. - The company is exploring strategic acquisitions to enhance its product portfolio, with a focus on companies that specialize in rare blood disorders[25]. - The company aims to expand its market presence through new product development and strategic acquisitions in the biopharmaceutical sector[96]. - The company plans to continue integrating industry resources and expanding rapidly to achieve its strategic goals[95]. Quality Management - The management highlighted the importance of maintaining high-quality standards, with a commitment to reducing product quality issues by 25% through improved quality control measures[25]. - The company has established a comprehensive quality management system to control product quality risks, which are critical for maintaining brand reputation[154]. - The company has a strong commitment to quality management, having been one of the first to pass the new GMP certification in China, ensuring high product safety and quality[93]. Production and Supply Chain - The company operates 13 plasma collection stations, all licensed by provincial health authorities, ensuring a stable supply of raw plasma[63]. - The company collected approximately 192 tons of raw plasma in the first half of 2021, a 25.68% increase compared to the same period last year[76]. - The company is facing a risk of insufficient raw material supply for blood products due to tight industry supply, and plans to expand plasma collection stations to mitigate this risk[149]. - The company has the qualification to establish new plasma collection stations and aims to increase the number of stations quickly, despite facing regulatory uncertainties[150]. Environmental Compliance - The company reported a total of 1.8764 tons of COD emissions, which is below the regulatory limit of 3.6286 tons[166]. - The company also reported 0.0731 tons of ammonia nitrogen emissions, well within the limit of 0.3299 tons[166]. - The company has implemented measures to ensure compliance with pollution discharge standards, with no exceedances reported[166]. - The company has established self-monitoring plans that include both automatic and manual monitoring methods to ensure compliance with environmental standards[184]. - The company has received environmental impact assessment approvals for various construction projects, including a 300-ton chemical raw material drug expansion project[182]. Corporate Governance and Shareholder Relations - The company has established a sound corporate governance structure and continuously improves the quality of information disclosure to protect shareholders' rights[198]. - The company held its first extraordinary general meeting of shareholders in 2021 with a participation rate of 42.71% on February 3, 2021[158]. - The company held its annual general meeting on May 17, 2021, with a participation rate of 42.36%[158]. - The company has undergone a board restructuring, with several new appointments made on February 4, 2021[162]. Employee Welfare and Community Engagement - The company emphasizes employee welfare, providing regular health checks and improving the working environment[199]. - The company maintains good relationships with suppliers and customers, adhering to principles of equality, mutual benefit, and win-win cooperation[200].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2018, representing a year-on-year increase of 15%[36] - The net profit attributable to shareholders was RMB 200 million, with a profit margin of 16.67%[36] - The company's operating revenue for 2018 was approximately ¥2.39 billion, representing a 71.72% increase compared to ¥1.39 billion in 2017[42] - The net profit attributable to shareholders for 2018 was approximately ¥469.17 million, an increase of 31.57% from ¥356.59 million in 2017[42] - The net cash flow from operating activities improved significantly to approximately ¥34.90 million, a 246.55% increase from a negative cash flow of ¥23.82 million in 2017[42] - The basic earnings per share for 2018 was ¥1.11, up 24.72% from ¥0.89 in 2017[45] - The total assets as of the end of 2018 reached approximately ¥5.07 billion, a 38.25% increase from ¥3.67 billion at the end of 2017[45] - The net assets attributable to shareholders increased by 52.72% to approximately ¥3.70 billion from ¥2.43 billion in 2017[45] - The company reported a diluted earnings per share of ¥1.11 for 2018, reflecting a 24.72% increase from ¥0.89 in 2017[45] - The company received government subsidies amounting to approximately ¥15.68 million in 2018, compared to ¥12.49 million in 2017[53] Shareholder Returns - The company plans to distribute a cash dividend of RMB 1.50 per 10 shares, totaling RMB 64.99 million based on the total share capital at the end of 2018[13] - The company has repurchased 7,026,300 shares, reducing the total share capital to 426,298,563 shares[13] - The company plans to continue its share repurchase program based on actual conditions, primarily for employee stock ownership plans or equity incentive plans[108] Market and Product Development - The company is focused on expanding its market presence and developing new products, although the approval process for new products can be lengthy and uncertain[9] - The company acknowledges the risk of not obtaining necessary product registration certificates, which could delay new product launches[9] - The company aims to establish itself as a "world-class blood product enterprise" and a benchmark in the pharmaceutical industry, focusing on high-quality medical products and services[72] - The company has expanded its product offerings to include diabetes medications, orthopedic drugs, and high-end anti-infection drugs, leveraging its competitive advantages in related fields[72] - The company has improved its marketing capabilities, resulting in an effective increase in market share for its main products[71] - The company operates in the blood product industry, with major products including albumin, immunoglobulin, and coagulation factors[62] - The company is one of the few in China with a complete range of blood products, including the most comprehensive specifications for albumin and intravenous immunoglobulin[63] - The company has a strong presence in the diabetes medication market through its subsidiary Tianan Pharmaceutical, which produces multiple diabetes products[66] - The company is a key distributor of blood products in Guangdong Province, a major market for blood products in China[68] Risks and Challenges - The company has identified risks related to the tight supply of raw materials, which could impact production capacity in the blood products sector[7] - The company is undergoing a goodwill impairment test due to acquisitions, which could negatively affect its financial performance if the acquired companies underperform[11] - The company is one of the few with the qualification to establish new plasma collection stations, but faces significant uncertainties due to national policies[8] - The company emphasizes the importance of product quality control, as any issues could lead to production halts and regulatory scrutiny[10] Research and Development - The company is actively advancing the research and development of blood products, including coagulation factor projects and immunoglobulin products[95] - The company has established a unique collaboration with Wytold Richard Lebing for blood product R&D, focusing on strategic planning and process optimization[98] - The company has successfully completed the consistency evaluation for Metformin Hydrochloride tablets (0.25g) and is progressing with other generic drug evaluations[99] - The company has withdrawn the registration application for Human Coagulation Factor VIII to improve clinical trial data before resubmission[97] - The company has established a new R&D center in Beijing to enhance its capabilities in developing specific immunoglobulin products and other blood products[186] Investments and Acquisitions - The company plans to raise up to ¥1 billion through a private placement of shares to fund the construction of a "thousand-ton blood product intelligent factory" project[104] - The company has completed the acquisition of a 27.77% stake in Wang Minyu Tian'an Pharmaceutical for RMB 14,757.63 million, with a cumulative investment of RMB 14,757.63 million[181] - The company has acquired 82% of Guangdong Fuda Pharmaceutical Co., Ltd. in November 2017, increasing its stake to 75% after a capital increase in January 2018[135] - The company purchased minority interests in several plasma stations for a total of 60 million yuan, resulting in 100% ownership of those stations[136] - The company increased its stake in Tianan Pharmaceutical to 89.6810% by acquiring an additional 6.325% for 34.815060 million yuan[137] Operational Efficiency - The company has optimized production processes to enhance production efficiency while ensuring product quality[71] - The sales volume of blood products increased by 33.21% to 2,458,766 bottles compared to the previous year[127] - The production volume of blood products rose by 30.24% to 2,624,581 bottles year-on-year[127] - The revenue from direct materials in the blood products business was 222,673,317.61 yuan, accounting for 83.82% of the total operating costs[132] Regulatory Environment - The blood products industry is experiencing increased regulatory scrutiny and consolidation, with global market share dominated by top companies like CSL and Grifols, which account for over 80%[199] - China's blood products industry has seen a reduction in operational companies to fewer than 30, with a trend towards increased concentration[200]

Financial Performance - The company's operating revenue for 2020 was ¥2,513,038,687.41, a decrease of 8.98% compared to ¥2,760,925,046.07 in 2019[32]. - The net profit attributable to shareholders for 2020 was ¥260,060,146.52, down 38.97% from ¥426,146,775.92 in 2019[32]. - The net profit after deducting non-recurring gains and losses was ¥248,721,937.76, a decrease of 39.16% compared to ¥408,795,458.34 in 2019[32]. - The basic earnings per share for 2020 was ¥0.61, down 39.00% from ¥1.00 in 2019[32]. - The total assets as of the end of 2020 were ¥5,158,535,284.56, a decrease of 1.87% from ¥5,256,690,601.18 at the end of 2019[32]. - The net assets attributable to shareholders increased by 5.01% to ¥4,107,903,650.55 from ¥3,911,734,528.48 at the end of 2019[32]. - The company reported a significant increase in net cash flow from operating activities, amounting to ¥718,583,048.24, compared to a negative cash flow of ¥114,512,591.73 in 2019[32]. - The company experienced a decline in the weighted average return on equity, which was 6.49% in 2020, down 4.89 percentage points from 11.38% in 2019[32]. - The total revenue for the year was approximately ¥2.51 billion, a decrease of 8.98% compared to the previous year[60]. - The net profit attributable to shareholders was approximately ¥260 million, down 38.97% year-on-year[60]. Market Position and Product Development - The company is focused on expanding its market presence and developing new products in the blood products sector[12]. - The company has a strong market position in blood products, which are considered strategic resources in China[47]. - The company’s main products include human albumin, immunoglobulin, and coagulation factors, with a total of 22 specifications[47]. - The company’s diabetes medication segment includes multiple products such as Glimepiride tablets and Metformin enteric-coated tablets, targeting Type 2 diabetes patients[52]. - The company has established a comprehensive product line in the diabetes medication market, covering four major categories of oral medications[52]. - The company aims to become a world-class blood product enterprise and a benchmark in the pharmaceutical industry[61]. - The company plans to accelerate the market development of new products such as PCC (Prothrombin Complex Concentrate) while enhancing academic and brand building in the blood products sector[193]. Risks and Challenges - The company faces a significant risk of raw material supply shortages due to the tight supply of healthy human plasma, which directly impacts production capacity[7]. - The company has a risk of not obtaining product registration certificates for new products, which could delay their market launch[9]. - The company acknowledges the risks associated with future plans and projections, urging investors to maintain awareness of potential uncertainties[6]. - The company recognizes the risk of delays in obtaining product registration certificates for new products, which could impact the launch of new offerings[197]. - There is a risk of goodwill impairment due to the acquisition of Tianan Pharmaceutical, Xinbai Pharmaceutical, and Fuda Pharmaceutical, which could negatively impact the company's financial performance if their future operations deteriorate[198]. Operational Efficiency and Management - The company emphasizes the importance of product quality control, as any issues could lead to production halts and reputational damage[10]. - The company has established a comprehensive quality management system to mitigate product quality risks, ensuring compliance with legal regulations and continuous improvement[198]. - The company has a stable management team with extensive experience in the blood product industry, enhancing its operational efficiency[72]. - The company signed a management framework agreement to oversee the daily operations of its subsidiary, ensuring better management of production and operations[97]. Investments and Acquisitions - The company has completed the acquisition of a 32% stake in Haikang Bio for RMB 3,594.45 million, achieving 100% of the planned investment[160]. - The company has invested RMB 2,872.83 million in the production of blood products, achieving only 2.90% of the planned investment[157]. - The company has committed RMB 24,261.37 million to supplement working capital, achieving 100% of the planned investment[157]. - The company has established a new subsidiary, Tunchang Boya Plasma Co., Ltd., with a registered capital of ¥10 million, of which the company subscribed ¥8 million, holding an 80% stake[116]. Plasma Collection and Supply - The company achieved a plasma collection volume of approximately 378 tons in 2020, representing a year-on-year growth of 1.61%, while the overall industry saw a decline of about 9%[47]. - The company operates 13 plasma collection stations, having recently received approval for a new station in Tunchang[47]. - The company plans to enhance raw plasma supply capabilities by optimizing existing collection stations and actively applying for new ones, with a focus on lean management to stabilize product yield and quality[193]. - The company is committed to increasing the number of plasma collection stations through acquisitions to ensure a stable supply of raw plasma[194]. Research and Development - The company has developed a biochemical drug research center and production base, focusing on peptide drugs and other therapeutic areas[53]. - The number of R&D personnel increased to 204, representing 12.61% of the total workforce[121]. - Research and development expenses amounted to ¥126,112,303.02, which is 5.02% of the operating revenue[121]. Regulatory and Compliance - The company is awaiting regulatory approvals for the share issuance to China Resources Pharmaceutical Group, which involves certain uncertainties[95]. - The company does not classify any non-recurring gains and losses as recurring, adhering to the relevant disclosure guidelines[42].

Financial Performance - The company's operating revenue for 2019 was ¥2,760,925,046.07, representing a 15.64% increase from ¥2,387,519,494.86 in 2018[27]. - The net profit attributable to shareholders for 2019 was ¥426,146,775.92, a decrease of 9.17% compared to ¥469,174,808.30 in 2018[27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥408,795,458.34, down 7.87% from ¥443,721,904.02 in 2018[27]. - The company's total assets as of December 31, 2019, were ¥5,256,690,601.18, reflecting a 3.62% increase from ¥5,073,150,178.05 at the end of 2018[27]. - The basic earnings per share for 2019 was ¥1.00, a decrease of 9.91% from ¥1.11 in 2018[27]. - The weighted average return on equity for 2019 was 11.38%, down 3.06 percentage points from 14.44% in 2018[27]. - The net cash flow from operating activities for 2019 was -¥114,512,591.73, a significant decline of 428.09% compared to ¥34,902,726.47 in 2018[27]. - The total non-recurring gains and losses for 2019 amounted to ¥17,351,317.58, compared to ¥25,452,904.28 in 2018[34]. - The company achieved total operating revenue of ¥2,760,925,046.07, a year-on-year increase of 15.64%[68]. - The company's net profit attributable to shareholders was ¥426,146,775.92, a decrease of 9.17% compared to the previous year[68]. Dividend Distribution - The company reported a cash dividend of 1.50 RMB per 10 shares, totaling 63,891,024.45 RMB distributed to shareholders[7]. - The cash dividend for 2018 was 64,998,729.45 yuan, accounting for 13.85% of the net profit attributable to ordinary shareholders[195]. - The company did not issue any bonus shares or increase capital from reserves during the 2019 profit distribution[190]. - The total cash dividend for 2019, including other methods, was 217,964,190.91 yuan, which is 51.15% of the net profit attributable to ordinary shareholders[195]. Business Operations and Strategy - The company aims to establish itself as a "world-class blood product enterprise" and a benchmark in the pharmaceutical industry, focusing on high-quality medical products and services[55]. - The company is actively expanding its diabetes medication business, with products like Glimepiride tablets and Metformin enteric-coated tablets among its offerings[49]. - The company is focusing on the development of high-end anti-infection drugs and expanding its product offerings in orthopedics and gastrointestinal areas[55]. - The company is committed to optimizing production processes to improve efficiency while ensuring product quality[54]. - The company is continuously advancing various projects to lay a solid foundation for future growth and development[54]. - The company aims to strengthen its blood product business by focusing on professional, large-scale, and international development strategies[173]. - The company plans to actively apply for the establishment of new plasma collection stations, leveraging its qualification as one of the few enterprises eligible for new station setups[179]. Market and Competitive Landscape - The blood products industry is experiencing consolidation, with the number of global blood product companies decreasing from 102 to less than 20, indicating a high market concentration[166]. - The pharmaceutical industry, which the company is expanding into, is supported by national policies and is expected to maintain high growth rates, although competition is intensifying[180]. Risks and Challenges - The company faces a significant risk of raw material supply shortages due to increased regulatory scrutiny and tight supply of human plasma, which directly impacts production capacity[5]. - The company has a risk of goodwill impairment due to the acquisition of Tianan Pharmaceutical, Xinbai Pharmaceutical, and Fuda Pharmaceutical, which could negatively affect financial performance if their operations deteriorate[6]. - The company faces risks related to raw material supply, as the availability of healthy human plasma is currently tight due to regulatory constraints[176]. - To mitigate supply risks, the company will enhance existing plasma collection capabilities and actively seek to establish new collection stations[178]. Research and Development - The company has established a new R&D center in Beijing to enhance its capabilities in developing specific immunoglobulin products and other blood products[158]. - The company will increase R&D investment and enhance collaboration with research institutions and enterprises to improve innovation capabilities and diversify its product line[174]. - The company’s R&D expenses increased significantly, impacting net profit due to enhanced product line development and marketing investments[68]. - The number of R&D personnel increased to 196 in 2019, representing 12.17% of the total workforce[110]. Financial Management and Investments - The company reported a significant increase in prepaid expenses by 157.89%, mainly due to advance payments for raw plasma[56]. - Short-term borrowings increased by 170.35%, primarily due to an increase in short-term bank loans[56]. - The company applied for a total of RMB 400 million in merger loans and other medium to long-term loans, primarily for the acquisition of Guangdong Fuda Pharmaceutical Co., Ltd. and other projects[132]. - The company has pledged all its shares in Guangdong Fuda Pharmaceutical to secure a loan of RMB 130 million from the Industrial and Commercial Bank of China[132]. - The company plans to use up to RMB 90 million of idle raised funds to temporarily supplement working capital, with a repayment period not exceeding 12 months[156]. Shareholder and Management Commitments - The controlling shareholder, Shenzhen Gaotejia Investment Group, committed to not transferring or entrusting the management of shares for 60 months post-IPO[196]. - Other shareholders, including Jiangxi Xinxing Biotechnology Development Co., pledged not to transfer or manage their shares for 36 months post-IPO[196]. - The controlling shareholder agreed to compensate Boya for any losses incurred due to non-fulfillment of commitments[200].

Financial Performance - The company's operating revenue for Q1 2021 was ¥624,118,627.05, representing a 2.38% increase compared to ¥609,594,359.83 in the same period last year[8]. - Net profit attributable to shareholders for Q1 2021 was ¥100,736,164.66, up 5.04% from ¥95,900,464.56 year-on-year[8]. - The net profit after deducting non-recurring gains and losses was ¥98,876,255.69, reflecting a 12.38% increase from ¥87,981,685.60 in the previous year[8]. - Basic and diluted earnings per share for Q1 2021 were both ¥0.24, a 4.35% increase from ¥0.23 in the previous year[8]. - Operating profit reached ¥122,974,479.86, reflecting a growth of 5.96% compared to the same period last year[28]. - The blood products business generated total operating revenue of ¥283,471,117.56, a year-on-year increase of 17.10%[28]. - The net profit from the blood products business was ¥84,430,633.20, representing a growth of 43.19% year-over-year[28]. - Net profit for the current period was ¥103,957,040.08, compared to ¥99,887,304.66 in the previous period, reflecting a growth of approximately 2.1%[79]. - Total operating revenue for the current period reached ¥624,118,627.05, an increase from ¥609,594,359.83 in the previous period[74]. Cash Flow and Assets - The net cash flow from operating activities increased significantly by 127.42%, reaching ¥159,306,575.70 compared to ¥70,048,130.64 in the same quarter last year[8]. - As of March 31, 2021, the company's cash and cash equivalents amounted to 668,822,235.13 RMB, a decrease from 753,894,253.78 RMB at the end of 2020[56]. - The total current assets decreased to 2,760,475,116.63 RMB from 2,927,663,474.49 RMB at the end of 2020[56]. - The company's total liabilities decreased from ¥966,078,096.11 to ¥708,746,713.24, a decrease of about 26.5%[62]. - Total assets at the end of the reporting period were ¥5,005,101,156.91, down 2.97% from ¥5,158,535,284.56 at the end of the previous year[8]. - Cash and cash equivalents decreased from ¥645,846,795.60 to ¥386,343,704.73, a drop of about 40%[66]. - The ending cash and cash equivalents balance decreased to 386,343,704.73 CNY from 457,940,294.04 CNY, a decline of 15.5%[97]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,886[11]. - The largest shareholder, Shenzhen Gaotejia Investment Group Co., Ltd., held 29.17% of the shares, amounting to 126,381,618 shares[12]. - Net assets attributable to shareholders increased by 2.45% to ¥4,208,580,030.35 from ¥4,107,903,650.55 at the end of the previous year[8]. Regulatory and Management Changes - The company has undergone a change in its board of directors and management team, with new appointments made on February 4, 2021[37]. - The company is subject to regulatory measures due to previous financial misconduct, and corrective actions have been taken[34]. - The company received a notice from the Shenzhen Stock Exchange regarding the suspension of the review for the issuance of A-shares to specific targets[33]. - The company is awaiting approval from relevant authorities for the issuance of shares related to the change in controlling shareholder[33]. Research and Development - R&D expenses decreased by 54.86% to ¥8,165,544.65 compared to the previous year[25]. - Research and development expenses decreased significantly to ¥2,611,824.06, down 76.3% from ¥11,043,867.32 in the prior period[83]. Financial Management - The company has fully recovered the funds related to the procurement of raw plasma, resolving previous financial occupation issues[33]. - The company has utilized 90,000.00 million RMB of idle raised funds to temporarily supplement working capital, which has been fully returned to the designated account[47]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[51]. - The company has not reported any violations regarding external guarantees during the reporting period[48]. Investment and Procurement - The top five suppliers accounted for 51.41% of the total annual procurement amount, with the largest supplier contributing CNY 79.476 million, representing 40.35%[32]. - The top five customers contributed 10.84% of the total annual sales, with the largest customer accounting for CNY 17.435 million, or 2.79%[32].